CVM
Price
$2.51
Change
+$0.05 (+2.03%)
Updated
May 23 closing price
Capitalization
223.95M
EDIT
Price
$1.55
Change
+$0.05 (+3.33%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
135.61M
67 days until earnings call
Interact to see
Advertisement

CVM vs EDIT

Header iconCVM vs EDIT Comparison
Open Charts CVM vs EDITBanner chart's image
Cel-Sci
Price$2.51
Change+$0.05 (+2.03%)
Volume$719.16K
Capitalization223.95M
Editas Medicine
Price$1.55
Change+$0.05 (+3.33%)
Volume$23.04K
Capitalization135.61M
CVM vs EDIT Comparison Chart
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVM vs. EDIT commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a StrongBuy and EDIT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (CVM: $2.46 vs. EDIT: $1.62)
Brand notoriety: CVM: Notable vs. EDIT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 1969% vs. EDIT: 73%
Market capitalization -- CVM: $223.95M vs. EDIT: $135.61M
CVM [@Biotechnology] is valued at $223.95M. EDIT’s [@Biotechnology] market capitalization is $135.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than CVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 7 bullish TA indicator(s).

  • CVM’s TA Score: 4 bullish, 6 bearish.
  • EDIT’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than CVM.

Price Growth

CVM (@Biotechnology) experienced а -64.55% price change this week, while EDIT (@Biotechnology) price change was +16.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.07%. For the same industry, the average monthly price growth was +3.12%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

CVM is expected to report earnings on May 15, 2025.

EDIT is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+1.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CVM($224M) has a higher market cap than EDIT($136M). EDIT YTD gains are higher at: 27.559 vs. CVM (-79.495). CVM has less debt than EDIT: CVM (11.1M) vs EDIT (35M).
CVMEDITCVM / EDIT
Capitalization224M136M165%
EBITDAN/A-233.11M-
Gain YTD-79.49527.559-288%
P/E RatioN/AN/A-
RevenueN/A32.3M-
Total CashN/A270M-
Total Debt11.1M35M32%
FUNDAMENTALS RATINGS
CVM vs EDIT: Fundamental Ratings
CVM
EDIT
OUTLOOK RATING
1..100
5017
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9764
P/E GROWTH RATING
1..100
50100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for CVM (98). This means that EDIT’s stock grew somewhat faster than CVM’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CVM (100). This means that EDIT’s stock grew similarly to CVM’s over the last 12 months.

EDIT's SMR Rating (98) in the Biotechnology industry is in the same range as CVM (100). This means that EDIT’s stock grew similarly to CVM’s over the last 12 months.

EDIT's Price Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for CVM (97). This means that EDIT’s stock grew somewhat faster than CVM’s over the last 12 months.

CVM's P/E Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that CVM’s stock grew somewhat faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME30.862.81
+10.02%
GameStop Corp
TSLA341.046.42
+1.92%
Tesla
BTC.X111673.2800001995.203100
+1.82%
Bitcoin cryptocurrency
SPY583.090.23
+0.04%
SPDR® S&P 500® ETF
AAPL201.36-0.73
-0.36%
Apple

CVM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CVM has been loosely correlated with NRXS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CVM jumps, then NRXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVM
1D Price
Change %
CVM100%
-45.45%
NRXS - CVM
59%
Loosely correlated
N/A
EYPT - CVM
37%
Loosely correlated
-4.60%
EDIT - CVM
34%
Loosely correlated
+8.00%
MGX - CVM
33%
Poorly correlated
+1.21%
PRTA - CVM
31%
Poorly correlated
-3.96%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+8.00%
CRSP - EDIT
54%
Loosely correlated
+1.46%
NTLA - EDIT
49%
Loosely correlated
+2.83%
PRME - EDIT
49%
Loosely correlated
+5.58%
ABCL - EDIT
47%
Loosely correlated
+0.50%
SLDB - EDIT
46%
Loosely correlated
+7.04%
More